Short-chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR–S6K pathway

J Park1, M Kim1, SG Kang1, AH Jannasch2, B Cooper2, J Patterson3 and CH Kim1,4,5

Microbial metabolites, such as short-chain fatty acids (SCFAs), are highly produced in the intestine and potentially regulate the immune system. We studied the function of SCFAs in the regulation of T-cell differentiation into effector and regulatory T cells. We report that SCFAs can directly promote T-cell differentiation into T cells producing interleukin-17 (IL-17), interferon-γ, and/or IL-10 depending on cytokine milieu. This effect of SCFAs on T cells is independent of GPR41 or GPR43, but dependent on direct histone deacetylase (HDAC) inhibitor activity. Inhibition of HDACs in T cells by SCFAs increased the acetylation of p70 S6 kinase and phosphorylation of S6, regulating the mTOR pathway required for generation of Th17 (T helper cell type 17), Th1, and IL-10+ T cells. Acetate (C2) administration enhanced the induction of Th1 and Th17 cells during Citrobacter rodentium infection, but decreased anti-CD3-induced inflammation in an IL-10-dependent manner. Our results indicate that SCFAs promote T-cell differentiation into both effector and regulatory T cells to promote either immunity or immune tolerance depending on immunological milieu.

INTRODUCTION

Gut commensal bacteria shape the gastrointestinal immune system and have profound effects on the adaptive immune system. Commensal bacteria produce a number of metabolites that regulate physiology, nutrition, and immunity in the host. Short-chain fatty acids (SCFAs), including acetate (C2), propionate (C3), and butyrate (C4), are highly produced from dietary fibers and other undigested carbohydrates in the colon. SCFAs are absorbed into colonic epithelial cells through simple diffusion or active transportation via solute transporters. C4 mostly remains in and is utilized by the epithelial cells, whereas C2 and C3 are readily transported to other cells and organs. SCFAs affect various aspects of gut physiology, barrier function, and metabolism. SCFAs regulate immune responses through their effects on a number of cell types, including colonocytes, neutrophils, and T cells.

Effector T cells, such as Th1 (T helper type 1) and Th17 cells, fight pathogens and can cause tissue inflammation. Regulatory T cells, such as IL-10+ (interleukin-10) T cells and FoxP3+ T cells, counterbalance the activities of effector immune cells. Importantly, the generation of both effector and regulatory T cells is profoundly influenced by gut microbiota. Although, SCFAs are linked to the expansion of colonic FoxP3+ T cells, the impact of SCFAs on regulation of effector T cells and non-FoxP3 regulatory T cells is unclear. In this study, we investigated the roles of SCFAs in regulation of T-cell differentiation into effector and IL-10+ regulatory T cells with the research focus on C2 and C3. Also investigated were the roles of cell-surface SCFA receptors (GPR41 and GPR43) and intracellular signaling events mediating the SCFA effect. We found that SCFAs, such as C2, C3, and C4 can selectively support the development of Th1 and Th17 effector cells and IL-10+ regulatory T cells depending on cytokine milieu and immunological context. We also provide insights into the intracellular signaling events regulated by SCFAs in T cells.

1Laboratory of Immunology and Hematopoiesis, Department of Comparative Pathobiology, West Lafayette, Indiana, USA. 2Metabolite Profiling Facility, Bindley Bioscience Center, West Lafayette, Indiana, USA. 3Department of Animal Science, West Lafayette, Indiana, USA. 4Weldon School of Biomedical Engineering, West Lafayette, Indiana, USA and 5Purdue Center for Cancer Research, Purdue University, West Lafayette, Indiana, USA. Correspondence: CH Kim (chkim@purdue.edu)

Received 18 December 2013; accepted 28 April 2014; published online 11 June 2014. doi:10.1038/mi.2014.44
RESULTS
C2 and C3 promote naive T-cell differentiation into Th1 or Th17 effector T cells depending on cytokine milieu.

It is a question of interest whether SCFAs can regulate the generation of effector T cells. To determine this, we differentiated naive CD4^+ T cells with C2 or C3 in vitro. C2 increased naive T-cell differentiation into Th17 cells in a dose-dependent manner (Figure 1a). C3 had the same positive effect on Th17 cell generation. Induction of Th1 cells in the presence of IL-12 was also increased by C2 or C3 (Figure 1a). Both C2 and C3 induced the transcription of the genes for IL-17A, IL-17F, RORγt, RORαt, T-bet, and IFN-γ, which are characteristically associated with Th17 cells or Th1 cells (Figure 1b). The optimal concentrations for this effect were 5–20 (C2) and 0.5–1 (C3) mM. The T cells induced in the presence of C2 or C3 in a Th1 polarization condition had increased expression of T-bet protein, but did not express FoxP3 (Figure 1c). Similarly, the T cells induced in a Th17 polarization condition did not express FoxP3 in the standard anti-CD3 (5 μg ml^-1) activation condition. However, we observed that FoxP3 expression together with RORγt was significantly enhanced by C2 or C3 in a low anti-CD3...
(1 μg ml⁻¹) activation condition (Supplementary Figure S1 online).

The function of SCFAs in inducing Th17 and Th1 cells is intriguing. We examined the colitogenic activity of the T cells, cultured in the presence of C2 in a Th17 polarization condition (C2-Th17 cells), in inducing tissue inflammation. We administered the cultured T cells into Rag1(−/−) mice. Unexpectedly, these T cells were not able to induce colitis as effectively as control T cells (Figure 2a,b). Compared to control T cells, C2-treated T cells were less effective in decreasing body weight (Figure 2a) and induced relatively mild inflammation in the colon despite the increased frequency of Th17 cells in the colon (Figure 2b,c). The mild inflammation is in line with the increased frequency of FoxP3⁺ T cells in the colon of the mice injected with C2-treated T cells (Figure 2c). Similar to the T cells cultured in a Th17 cell condition, C2-treated T cells prepared in a Th1 condition were less inflammatory despite increased Th1 and Th17 cells in the colon of the host mice (Figure 2d–f). These results indicate that C2-treated T cells, while enhanced in expression of effector cytokines, are not highly inflammatory or would not become highly inflammatory cells in vivo.

C2 and C3 induce IL-10-producing T cells admixed with effector T cells
SCFAs can promote IL-10 expression in leukocytes and T cells,10,19 and this may explain the relatively low inflammatory activity of C2-treated effector T cells. We examined the

![Figure 2](image-url)

*Significant differences from the control group or between indicated groups (P<0.05). IFN-γ, interferon-γ; PBS, phosphate buffered saline.
possibility that effector T cells admixed with IL-10-producing T cells are made in response to SCFAs. Expression of IL-10 in both intracellular and secreted forms was induced by C2 or C3 in all T-cell polarization conditions (Tnp, Th17, and Th1) examined in this study (Figure 3a–d). Many T cells co-expressed IL-10 and IFN-γ (Figure 3a). IL-10 induction by SCFAs was also confirmed at the mRNA level (Figure 3d). Most of these IL-10 producers induced in Tnp, TH1, or Th17 condition did not express FoxP3 (Supplementary Figure S2). Even the FoxP3<sup>+</sup> T cells and IL-10<sup>+</sup> T cells induced in a Th17 polarization condition with a low level of anti-CD3 (1 μg ml<sup>−1</sup>) were distinct populations.

Because of the high IL-10 expression by C2-treated T cells, we assessed their regulatory activity on responder T cells. C2-treated T cells were highly efficient in suppressing the proliferation of responder T cells (Figure 3e). They were significantly more suppressive than control T cells. However, the C2-treated T cells prepared from IL-10<sup>−/−</sup> mice were unable to suppress responder T cells (Figure 3e), indicating the importance of IL-10 in the regulatory function of C2-treated T cells.

Figure 3  Short-chain fatty acids (SCFAs) induce interleukin-10 (IL-10)-producing CD4<sup>+</sup> or CD8<sup>+</sup> T cells admixed with effector T cells. (a) The cytokine phenotype of CD4<sup>+</sup> T cells cultured in Tnp, Th17 (T helper type 17), or Th1 condition with indicated SCFA was determined by flow cytometry. (b) Dose-dependent effects of C2 and C3 on the induction of IL-10<sup>+</sup> CD4<sup>+</sup> T cells. Conditioned media were examined for secreted IL-10 (c) and IL-10 mRNA (d). (e) The suppressive activity of control and C2-treated T cells on the proliferation of responder T cells was examined. Suppressor T cells were co-cultured with responder cells (CFSE-labeled CD4<sup>+</sup>/CD25<sup>+</sup> T cells) in the presence of anti-CD3 and irradiated T-cell-depleted splenocytes as antigen-presenting cells for 3 days before flow cytometric analysis. C2-treated suppressor T cells were prepared from the culture of naive CD4<sup>+</sup> T cells, isolated from WT or IL-10<sup>−/−</sup> mice, for 5–6 days in the presence of C2 (10 mM) in a Th1 cell-polarization condition. (f) SCFAs also induce expression of IL-10 in CD8<sup>+</sup> T cells. Total CD8<sup>+</sup> T cells were activated with anti-CD3/28 in a Tc1 (IL-2, IL-12, and anti-IL-4) or Tc17 (TGFβ1, IL-6, IL-1β, IL-23, IL-21, TNFα, anti-IL-4, and anti-IFN-γ) polarization condition for 5–6 days. If not indicated, the concentrations of SCFAs were 10 mM (C2) or 1 mM (C3) for all experiments. Representative or pooled data obtained from 3–4 experiments are shown. * Significant differences from blank groups or between indicated groups (P<0.05). CFSE, carboxyfluorescein diacetate succinimidyl ester; WT, wild type.
So far, we examined the SCFA effect on CD4\(^+\) T cells. A question of interest is whether SCFAs impact other T cells, such as CD8\(^+\) T cells. We found that SCFAs highly induced the expression of IL-10, IFN-\(\gamma\), and IL-17 in CD8\(^+\) T cells in both Tc1- and Tc17-cell conditions (Figure 3f).

We fed mice with C2 in drinking water and found that this C2 feeding significantly increased C2 concentration in cecal contents and colon tissues (Figure 4a). However, the C2 feeding did not alter C3 or C4 in the cecal contents or intestinal tissues. C2 administration did not change the frequencies and numbers of Th17 and Th1 cells in a normal condition without infection. The positive impact of C2 feeding on clearance of *Citrobacter rodentium* has been determined,\(^{11}\) but the impact on induction of effector T cells during anti-*C. rodentium* infection has been unclear. We infected the C2-fed mice with *C. rodentium* to assess changes in effector T cells during an active immune response. Although, the C2 administration did not change the Th1 and Th17 cells in the absence of infection, it significantly changed the frequencies of Th1 and Th17 cells in the cecum during the infection (Figure 4b,c and Supplementary Figure S3). These results indicate that SCFAs effectively promote effector T cells during an active immune response, but not in the steady state.

In contrast to Th1 and Th17 cells, IL-10 \(^-\) CD4\(^+\) T cells were increased in frequency in the cecum, but not the lymphoid tissues of C2-fed mice in the steady state (Figure 4b,c). Interestingly, the infection with *C. rodentium* unexpectedly decreased IL-10 \(^+\) T cells in the cecum. These results indicate that the SCFA effect on IL-10 \(^+\) T cells can be modulated by an ongoing immune response.

Anti-CD3 injection (intraperitoneal) induces inflammation in the intestine and also increases IL-10 \(^+\) T cells.\(^{20,21}\) We utilized this method to assess the booster effect of C2 on the anti-CD3-induced T-cell differentiation and tissue inflammation. C2 administration increased the frequency of IL-10 \(^+\) T cells and effector T cells (Th1 and Th17) in systemic sites, such as spleen and mesenteric lymph node (Figure 5a–c). The frequency and number of IL-10 \(^+\) T cells in the colon was already high (~two times of the control mice) after anti-CD3 administration (intraperitoneal) and was not further increased in C2-fed mice (Figure 5a). Also, increased were Th17 and Th1 cells in the spleen and mesenteric lymph node, but not the intestine (Figure 5b,c). Anti-CD3 administration (intraperitoneal) induced tissue hypertrophy and inflammation mainly in the terminal ileum. This inflammation in the ileum was noticeably decreased with C2 administration in drinking water (Figure 5d). However, C2 was not significantly protective in anti-CD3-injected IL-10 (−/−) mice, indicating a key role for IL-10 in mediating the suppressive C2 effect (Figure 5d).

**The SCFA effect on T cells is independent of GPR41 or GPR43**

SCFAs activate G-protein-coupled receptors, such as GPR41 and GPR43.\(^{22}\) It is a question of interest whether GPR41 and GPR43 are required for the SCFA effect on T cells. Compared to colonic epithelial cells (which express GPR41 and GPR43) and Gr-1 \(^+\) cells (which express GPR43), the CD4\(^+\) T cells isolated from the colon and spleen did not express these genes at significant levels (Figure 6a,b). Moreover, cultured CD4\(^+\) T cells (with or without SCFAs) and marrow-derived dendritic cells do not express the receptors at significant levels (Figure 6a).

Utilizing the T cells isolated from the mice deficient in GPR41 or GPR43, we examined the function of these receptors in mediating the SCFA effect *in vitro*. The effect of SCFAs on inducing the expression of IL-10, IFN-\(\gamma\), and/or IL-17 was intact in GPR41- or GPR43-deficient CD4\(^+\) T cells (Figure 6c,d). We examined also the frequencies of IL-10 \(^+\) T cells and effector T cells in various organs of GPR41- and GPR43-deficient mice (Figure 7a). No significant difference among the mice in the frequencies of Th17, Th1, and IL-10 \(^+\) T cells was observed. Moreover, the increase of IL-10 \(^+\) T cells in response to C2 administration was not abolished in the GPR41- and GPR43-deficient mice (Figure 7b). Thus, GPR41 and GPR43 are dispensable for the SCFA effect on T-cell differentiation.

**SCFAs inhibit histone deacetylases in a GPR41-/GPR43-independent manner and regulate p70 S6 kinase-rS6 in T cells**

SCFAs can inhibit histone deacetylases (HDACs).\(^{23,24}\) It has been recently reported that HDAC activity could be regulated in a GPR43-dependent manner.\(^{10}\) The concept that SCFA receptors are really involved in the inhibition of HDACs by SCFAs is questionable because SCFAs can bypass the surface receptors and enter cells to exert their inhibitory activity.\(^{25}\) Employing a cell-based HDAC assay where SCFAs have to enter T cells to inhibit HDACs, we assessed the need for GPR41 or GPR43 in the inhibition of HDACs in T cells. As expected, activated CD4\(^+\) T cells had high HDAC activity (Figure 8a), and trichostatin A (TSA; a class HDAC I and II inhibitor) was effective in suppressing the HDAC activity in T cells. The HDAC activity in T cells was suppressed by C2, C3, and C4 in a dose-dependent manner. Interestingly, the HDAC inhibitor activity of SCFAs was not diminished in T cells deficient in GPR41 or GPR43 (Figure 8a). We, next, tested whether HDAC inhibition by TSA can affect T-cell differentiation in a manner similar to C2 or C3. HDAC inhibition by TSA increased the expression of IL-10, IFN-\(\gamma\) and IL-17 in T cells (Figure 8b). This indicates that the HDAC inhibition activity is sufficient to mediate the SCFA effect on T cells.

The mTOR pathway is a key integrator of nutrient, energy, and metabolic status and controls T-cell differentiation.\(^{26–28}\) We examined whether SCFAs or HDAC inhibition can alter the activity of the mTOR pathway to affect T-cell differentiation and cytokine phenotype. Both SCFAs (C2 and C3) and TSA greatly enhanced the phosphorylation of the ribosomal protein S6 (rS6), a major target of the mTOR pathway (Figure 9a). Phosphorylation of rS6 due to T-cell activation normally peaks at 12 h and goes down by 60 h, but it was highly sustained with C2 or C3 (Figure 9a). These results led us to examine p70 S6 kinase (S6K), which phosphorylates rS6. Acetylation of S6K at lysine 516 is induced by co-activator p300/CBP and HDAC
inhibitors, and this could provide a potential regulatory point for the mTOR pathway. C2, C3, and TSA, all induced the acetylation of S6K in T cells (Figure 9b).

Because of the implication of the mTOR–S6K pathway in the SCFA effect on T cells, we assessed the effect of rapamycin (an mTOR inhibitor) on SCFA-induced IL-10 expression. We

**Figure 4** Impact of infection on the Short-chain fatty acid (SCFA) effect on effector vs. IL-10 T cells. (a) The concentrations of SCFAs in the cecal contents and intestinal tissues of acetate (C2)-fed mice were determined by liquid chromatography–mass spectrometry. (b and c) Some of the C2-fed mice were infected with *Citrobacter rodentium*. Changes in Th17 (T helper type 17), Th1, and IL-10 T cells in indicated tissues 14 days after oral infection with *C. rodentium* were examined by flow cytometry. Pooled data (b; n = 7–9) and representative dot plots (c) are shown. *Significant differences (P < 0.05). C3, propionate; C4, butyrate; IFN-γ, interferon-γ; MLN, mesenteric lymph node.*
found that rapamycin was effective in suppressing the C2- or C3-induced cellular expression and secretion of IL-10 in T cells (Figure 9c). The SCFA-dependent increase of IL-10⁺, Th1, and Th17 cells was also suppressed by rapamycin. Furthermore, metformin, an AMPK activator, which suppresses the mTOR pathway, effectively abolished the SCFA effect on T cells (Figure 9d). In a manner similar to IL-6, SCFAs activated STAT3 (Figure 9e), which is typically activated downstream of mTOR and involved in the expression of IL-10 and IL-17. Extracellular signal-regulated kinase is implicated in the
The expression of IL-10 by Th1 cells and is activated by the signals from GPR41 or GPR43 in epithelial cells. SCFAs, however, had no detectable effect on extracellular signal-regulated kinase activation in T cells (Supplementary Figure S4). Overall, these results indicate that SCFAs inhibit HDACs and regulate the mTOR–S6K pathway required for T-cell differentiation into effector and regulatory T cells.

C4 also promotes rS6 phosphorylation and T-cell production of IFN-γ, IL-17, and/or IL-10

So far, we examined the function of C2 and C3. We studied whether C4 has a similar activity as C2 and C3 in regulating T cells. C4 increased the phosphorylation of rS6 in most T cells at 0.5 mM, an effective concentration lower than that of C2 or C3 (Figure 10a). Moreover, C4 promoted the differentiation of naive CD4⁺ T cells into IL-10 producers in all T-cell polarization conditions tested (Tnp, Th1, and Th17; Figure 10b). C4 also enhanced the induction of IFN-γ and IL-17 in Th1- and Th17-polarization conditions, respectively. Thus, C4 is highly similar to C2 and C3 in regulating T-cell differentiation.

DISCUSSION

Our results indicate that SCFAs can directly affect T-cell differentiation. SCFAs enhance T-cell differentiation into effector T cells, such as Th1 and Th17 cells, admixed with anti-inflammatory IL-10⁺ regulatory T cells. This function of SCFAs is mediated by their GPR41 or GPR43-independent HDAC inhibitor activity and subsequent enhancement of mTOR–S6K activity required for T-cell differentiation and cytokine expression.

SCFAs activate cell-surface receptors, such as GPR41 and GPR43, but can be readily absorbed into any cell types. This property allows SCFAs to bypass the cell-surface SCFA receptors to regulate even the cells that do not highly express GPR41 or GPR43. It has been debated whether T cells express...
Our results indicate that T cells do not express GPR41 and GPR43 at functional levels, as reported previously. This is supported by our data that HDAC inhibition and regulation of T-cell differentiation by SCFAs normally occur even in T cells deficient in GPR41 and GPR43. This is consistent with the fact that extracellular signal-regulated kinases, typically activated downstream of GPR41 and GPR43, are not activated in T cells by SCFAs.

Once entered into T cells undergoing activation, SCFAs effectively suppress HDACs as demonstrated in this study. Acetylation of proteins, including histones, transcription factors, and various signaling molecules by HDACs can alter the functions of modified proteins. A pathway, important for T-cell differentiation and affected by HDAC inhibition demonstrated in this study, is the mTOR–S6K pathway. The mTOR pathway promotes the expression of key effector and regulatory cytokines, such as IL-10, IFN-γ, and IL-17. This is involved in the expression of cytokines (IL-10, IFN-γ, and IL-17) in T cells.

Our results indicate that the C2 function in regulation of T cells is modulated by cytokine milieu and immunological context. We observed that IL-10+ T cells were increased by SCFAs in the steady condition in vivo, whereas effector T cells were increased by C2 only during active immune responses. Moreover, IL-10 expression was promoted in all T-cell polarization conditions tested in this study, whereas the expression of IL-17 and IFN-γ was promoted specifically in respective polarization conditions. IL-10 production by effector T cells is an important negative feedback mechanism to rein in the inflammatory activities of effector T cells. This selective enhancement of effector vs. IL-10+ T cells would be beneficial to the host in promoting immunity with the built-in negative feedback function of IL-10. An interesting observation made in this study in this regard was that induction of FoxP3+ T cells by SCFAs can occur in a low TCR-activation condition. Taken together, SCFAs can induce both effector and regulatory T cells, including IL-10+ T cells and FoxP3+ T cells in appropriate conditions.
It is plausible that SCFAs affect non-T cells to indirectly affect T cells in vivo. Such indirect effects are mediated by non-T cells, such as epithelial cells, for example, and may account for the increased number of FoxP3+ T cells in the colon by SCFAs. C4 can work through GPR109A on macrophages and dendritic cells to indirectly induce IL-10+ T cells and FoxP3+ T cells. A mixture of human Clostridia strains can produce SCFAs and promote the induction of FoxP3+ T cells in the colon. In this regard, C4 can suppress HDACs to induce FoxP3 expression. Moreover, SCFAs can affect other organs, such as lungs and regulate allergic hypersensitivity. More studies are required to precisely determine the functions of SCFAs in the regulation of the immune system and inflammatory diseases.

Our study provides an example how the host immune system harnesses commensal bacterial metabolites for the promotion of specialized effector and regulatory T cells. The results identified SCFAs as key gut metabolites important for T-cell differentiation into effector and regulatory cells in the body depending on SCFA levels and immunological context. The results have many practical ramifications in the regulation of tissue inflammation and immunity.

### METHODS

**Mice.** All experiments with animals in this study were approved by the Purdue Animal Care and Use Committee (PACUC). Rag1(-/-) (B6.129S7-Rag1tm1Mom/J) mice and IL-10(-/-) mice were originally from the Jackson laboratory. C57BL/6 mice were originally from Harlan (Indianapolis, IN) and CD45.1 C57BL/6 mice were originally from the Jackson Laboratory. GPR43(-/-) mice were originally from Deltagen (San Mateo, CA, USA), and GPR41(-/-) mice were obtained from Dr M. Yanagisawa (UT Southwestern Medical Center at Dallas). All mice were produced at the Purdue Life Science Animal Facility and fed with a regular rodent diet (Purina 5053).

**Cell isolation.** CD4+ T cells were isolated from the spleen and lymph nodes, using the CD4+ T cell isolation kit (Miltenyi, San Diego, CA). Cells expressing CD8 (clone 53-6.7), CD19 (clone 6D5), CD25 (clone 3C7), CD44 (clone IM7), and CD69 (clone H1.2F3) were further depleted with indicated phycoerythrin-conjugated antibodies and anti-phycoerythrin Miltenyi beads to isolate naive CD4+ T cells. CD8+ cells were isolated by the CD8+ T cell isolation kit (Miltenyi), and cells expressing CD4, CD19, CD25, CD44, and CD69 were further depleted as described for naive CD4+ T cells. Colonic epithelial cells were positively isolated from ethylenediaminetetraacetic acid-extracted epithelial cells with biotin-conjugated anti-CD326 (clone Ep-CAM) and anti-biotin Miltenyi beads. Colonic T cells were enriched from colonic lamina propria cells by depleting non-T cells with biotin-conjugated anti-CD11c (clone N418), CD19 (clone 6D5),
CD326 (clone Ep-CAM), and Gr-1 (clone RB6-8C5) antibodies. CD4+ cells were positively selected with phycoerythrin-conjugated anti-CD4 and anti-phycoerythrin Miltenyi beads. Marrow Gr-1+ cells were positively selected from bone marrow cells with biotin-labeled anti-GR-1 antibody (clone RB6-8C5) and anti-biotin Miltenyi beads. In general, the purity of the isolated cells was 495%. The antibodies were from either BioLegend or eBioscience (San Diego, CA).

T-cell differentiation in vitro. To induce effector T cells and Tregs in vitro, naive CD4+ or CD8+ T cells (1 x 10^5 per well) were isolated from wild type (WT), GPR41(-/-/-), and GPR43(-/-/-) mice and activated with plate-coated anti-CD3 (5 μg/ml) and soluble anti-CD28 (2 μg/ml) in 96-well plates for 5–6 days in the presence or absence of sodium acetate (C2), sodium propionate (C3), or sodium butyrate (C4) at indicated concentrations. In some experiments where low TCR activation is required, the anti-CD3 was used at 1 μg/ml. RPMI-1640 medium (10% fetal bovine serum) containing rapamycin (25 nM, Enzo), metformin (1 mM), or TSA (10 nM, Enzo) were used for the T-cell culture. For Th17/Tc17 cells, hTGF-β1 (5 ng/ml), mIL-6 (20 ng/ml), mIL-1β (10 ng/ml), mIL-23 (10 ng/ml), mIL-21 (10 ng/ml), mTNF-α (20 ng/ml), anti-mIL-4 (11B11, 10 μg/ml), and anti-mIFN-γ (XMG1.2, 10 μg/ml) were used. For Th1/Tc1 cells, hIL-2 (100 U/ml), mIL-12 (10 ng/ml), and anti-mIL-4 (10 μg/ml) were used. For the non-polarized condition (Tnp), hIL-2 (100 U/ml) was used.

Flow cytometry. For intracellular staining of IL-10, IL-17, and IFN-γ, cells were stained first for surface antigens with antibodies.

Figure 9 Short-chain fatty acids (SCFAs) enhance mTOR activity. (a) Activation of the mTOR pathway based on rS6 phosphorylation in CD4+ T cells. T cells were activated with anti-CD3/CD28 and interleukin-2 (IL-2) in the presence or absence of C2 or C3, and examined by flow cytometry. (b) Acetylation of S6K in activated T cells in the presence of C2, C3, or TSA. The antibodies used for immunoprecipitation and western blotting were anti-acetylated lysine and anti-S6K, respectively. (c) The effect of rapamycin on SCFA-dependent generation of Th-cell subsets was assessed. Naive CD4+ T cells were cultured in a Tnp, Th1, or Th17 polarization condition for 5–6 days in the presence of C2 (10 μM), C3 (1 μM), and/or rapamycin (25 μM), and the cytokine phenotype of cultured T cells was examined by flow cytometry and enzyme-linked immunosorbent assay (ELISA). (d) AMPK activation suppressed the SCFA effect on T-cell differentiation. Naive CD4+ T cells were cultured with SCFAs and/or metformin in indicated polarization conditions for 5–6 days, and frequencies of indicated T-cell subsets were examined. The dot plots were from the data obtained in a Th1 condition. (e) Activation of STAT3 by C2 or C3 was examined. CD4+ T cells were activated for 3 days with anti-CD3/28 and then examined for phosphorylation of STAT3. Representative and pooled data obtained from at least three experiments are shown. *Significant differences from blank or control groups (P<0.05). C2, acetate; C3, propionate; p-rS6, phosphorylation of the ribosomal protein S6; IFN, interferon; Th, T helper; TSA, trichostatin A.
Signaling Technology, Danvers, MA). 2) (Thr202/Tyr204; 137F5) were used for flow cytometry (all from Cell
tombed 96-well plates for 3 days at the indicated ratios in the presence of
well) were isolated from the spleen of CD45.1 congenic mice, and
for their (C2-treated cells) or absence (control cells) of C2, were examined
weight change and activity. All mice were killed once some mice
mALR1-deficient (B6.129S7-Rag1tm1Mom/J) mice (1 million cells per mouse). The mice were monitored daily for
mTOR activation or STAT3 activation, mouse
m) cells, were activated with anti-CD3/CD28 for 3 days for rS6 phosphorylation and for 5–6 days in a Tnp, Th17, or Th1 condition for T-cell
differentiation at indicated concentrations of C4. Representative and pooled data obtained from at least three experiments are shown. *Significant
differences from blank or control groups (P<0.05). IFN, interferon; IL, interleukin; p-rS6, phosphorylation of the ribosomal protein S6; Th, T helper.

Assessment of in vitro suppressive activity. Cultured T cells, prepared as described above in a Th1 condition in the presence (C2-treated cells) or absence (control cells) of C2, were examined for their in vitro suppression activity on freshly isolated CD4+ CD25 T cells. Freshly isolated CD4+ CD25 T cells (responders, 5 x 10^6 per well) were isolated from the spleen of CD45.1 congenic mice, and indicated cultured T cells (suppressors) were co-cultured in U-bottomed 96-well plates for 3 days at the indicated ratios in the presence of anti-CD3 (2.5 μg ml^-1) and 10^5 irradiated T-cell-depleted splenocytes as antigen-presenting cells. Dilution of carboxyfluorescein diacetate succinimidyl ester was assessed by flow cytometry.

T-cell transfer into Rag1(−/−) mice. The control and C2-treated T cells (prepared in a Th17 or Th1 condition) were separately injected intraperitoneally into Rag1-deficient (B6.129S7-Rag1tm1Mom/J)) mice (1 million cells per mouse). The mice were monitored daily for weight change and activity. All mice were killed once some mice experienced 20% weight loss or were moribund. Intestine and other tissues were examined for the frequencies of Th1, Th17, and FoxP3+ T cells by flow cytometry. Intestinal tissues were embedded in paraffin, cut into 6-μm-thick sections, and stained with hematoxylin and eosin. Tissue inflammatory scores were assessed based on the degree of leukocyte infiltration and mucosal hyperplasia on a scale of 0–4. The histological images were obtained with a widefield Leica microscope equipped with a color camera at 100 magnification (scale bar: 200 μm).

In vivo administration of C2 and assessment of effector and regulatory T-cell subsets. WT C57BL/6, GPR43(−/−), and GPR41(−/−) mice were kept on drinking water containing C2 (200 μm, pH 7.5) from 3 weeks of age for 6–8 weeks. Drinking water was replaced once a week. Mice were examined for the frequencies of indicated T-cell subsets in various organs by flow cytometry. C2-fed WT or IL-10(−/−) mice were injected with anti-CD3 (15 μg per mouse, clone 145-2C11) at two time points (0 and 48 h) and were killed at 52 h after the first injection of anti-CD3. Alternatively, mice were infected with C. rodentium (DBS100, 10^10 CFU per mouse) via oral gavage, as described previously.10 Mice were killed 2 weeks post-infection, and various tissues were examined for frequencies of T-cell subsets with flow cytometry and tissue inflammation based on the degree of leukocyte infiltration and mucosal hyperplasia, and loss of villi on a scale of 0–5.

Assessment of HDAC inhibitor activity and S6K acetylation in T cells. HDAC Cell-Based Activity Assay Kit (Cayman Chemical, Ann Arbor, MI) was used to measure HDAC activity in activated T cells. Naive CD4+ T cells, isolated from WT or indicated knockout mice, were pre-activated with anti-CD3 and CD28 for 2 days. The activated T cells were incubated with C2, C3, or TSA for 2 h, and processed to measure the HDAC inhibitor activity of the reagents according to the manufacturer's protocol.

CD4+ T cells were activated with anti-CD3/CD28 and hIL-2 (100 U ml^-1) in the presence or absence of C2 (10 μg/ml), C3 (1 μg/ml), or TSA (10 μg/ml) for 3 days. Cultured cells (1 x 10^6 cells) were lysed, pre-cleared by Protein A agarose beads, and incubated with acetylated-lysine antibody (9441, Cell Signaling Technology) overnight at 4°C.
Antigen–antibody complexes were precipitated with Protein A agarose beads. Immunoprecipitates or total cell lysate (40 μg of protein per well) were separated with SDS-polyacrylamide gels and then transferred onto nitrocellulose membranes (Bio-Rad, Hercules, CA). After blocking 1 h in a nonfat dried milk, membranes were incubated with mAb to p70 S6 Kinase (49D7, biotinylated, Cell Signaling Technology) overnight at 4°C. The membranes were developed with HRP-streptavidin (Biologend) and the ECL detection system (GE Healthcare, Pittsburgh, PA) using a G:BOX (Syngene, Pittsburg, PA).

Measurement of SCFAs in intestinal tissues and cecal contents. Intestinal tissues or cecal contents (100 mg) were homogenized in 900 μl of water and 1.4 mm ceramic beads using a Precellys 24 homogenizer. The homogenates were labeled with regular aniline (12C6), and external SCFA standard solution (10 mg ml−1) of C2, C3, and C4) was labeled with aniline-13C6 using N-(3-Dimethylamino-propyl)-N′-ethylcarbodiimide hydrochloride (2 mg per sample). Crotonic acid (final 0.1 mg ml−1) was used as an internal standard. The labeling mixture was incubated for 2 h, and triethylamine was added to stop the labeling reaction. Samples and standard reaction solution were mixed (1:1) and analyzed with an Agilent 6460 Triple Quad LC/MS System (Agilent Technologies, Santa Clara, CA). SCFAs were separated with a C18 column (4.6 × 150 mm) at gas temperature of 325°C, gas flow rate 81 min−1, nebulizer pressure 45 p.s.i., sheath gas temperature 250°C, sheath gas flow rate 7 l min−1, capillary voltage +3500 V, and nozzle voltage +1000 V. SCFA concentrations in samples were determined based on peaks of interest related to this work.

Quantitative real-time PCR analysis and enzyme-linked immunosorbent assay. Total RNA was extracted with TRIzol (Invitrogen), and cDNA synthesis was performed with SuperScript II Reverse Transcriptase (Invitrogen, Grand Island, NY). Quantitative real-time PCR was performed with Maxima SYBR Green/ROX qPCR Master Mix (2X; Fermentas, Waltham, MA). The primers used were: IL-10 (5′-CCAGCTGGCAAACATACCTGCT-3′ and 5′-CATCATGTATGCTTCTATGCAG-3′); IL-17A (5′-GACTCTCCAGGCAATG-3′ and 5′-GGGCTCCTGTATTAGG-3′); IL-17F (5′-CCATGGGATTACACACATCCT-3′ and 5′-TTGTATGCGAGTTGTCAAG-3′); RoRγt (5′-AGGACCCTGATCCAGTGTTC-3′ and 5′-TGAAGGCGGTTTGCAAACT-3′); RoRγ (5′-GGTGCATTCGGAAAAT-3′ and 5′-GGGCGGATTACATTTCA-3′); IFN-γ (5′-AGACAGATAAGGTCCTCAGCG-3′ and 5′-CCAATACGAGCGCTAAT-3′); G-CSF (5′-GTCGAGCCGACTACG-3′ and 5′-TGGTGCGCTGAAATTT-3′); T-bet (5′-ATGGCCCGTGAATTTGGAATG-3′ and 5′-ACCTCGCAGAGCAATG-3′). Gene expression levels were normalized by β-actin levels. Enzyme-linked immunosorbent assay of secreted IL-10 was performed with anti-IL-10 antibody (JESS-2A5) and a biotinylated anti-IL-10 antibody (JESS-16ES).

Statistical analysis. Student’s paired t-test (two tailed) was used to determine the significance of differences between two groups. Mouse weight-change data was analyzed with a repeated measures analysis of variance (SAS, version 9.2, SAS Institute, Cary, NC). P values ≤0.05 were considered significant.

SUPPLEMENTARY MATERIAL is linked to the online version of the paper at http://www.nature.com/mi

ACKNOWLEDGMENTS We thank J Lee, B Ulrich, and A Kaur (Purdue University) for their helpful inputs. This study was supported, in part, by grants from the National Multiple Sclerosis Society, NIH (R01AI074745, R01DK076616, 1S1OR082289, and R01AI080769), and Crohn’s and Collitis Foundation of America to CHK. JHP performed experiments, analyzed data, and prepared most of the figures with experimental contributions from MHK, SGK, AHJ, BC, and JP. CHK designed the study, analyzed data, and drafted the manuscript with JHP. None of the authors have a financial interest related to this work.

DISCLOSURE The authors declared no conflict of interest.

REFERENCES
1. Lee, Y.K. & Mazmanian, S.K. Has the microbiota played a critical role in the evolution of the adaptive immune system? Science 330, 1768–1773 (2010).
2. Kamada, N. & Nunez, G. Role of the gut microbiota in the development and function of lymphoid organs. J. Immunol. 190, 1389–1396 (2013).
3. Keeney, K.M. & Finlay, B.B. Enteric pathogen exploitation of the microbiota-generated nutrient environment of the gut. Curr. Opin. Microbiol. 14, 92–98 (2011).
4. Flint, H.J., Scott, K.P., Louis, P. & DUNCAN, S.H. The role of the gut microbiota in nutrition and health. Nat. Rev. Gastroenterol. Hepatol. 9, 577–589 (2012).
5. Macfarlane, S. & Macfarlane, G.T. Regulation of short-chain fatty acid production. Proc. Nutr. Soc. 62, 67–72 (2003).
6. Kamp, F. & Hamilton, J.A. How fatty acids of different chain length enter and leave cells by free diffusion. Prostaglandins Leukot. Essent. Fatty Acids 75, 143–159 (2006).
7. Cummings, J.H., Pomare, E.W., Branch, W.J., Naylor, C.P. & Macfarlane, G.T. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut 28, 1221–1227 (1987).
8. Ziegler, T.R., Evans, M.E., Fernandez-Estivariz, C. & Jones, D.P. Trophic and cytoprotective nutrition for intestinal adaptation, mucosal repair, and barrier function. Annu. Rev. Nutr. 23, 229–261 (2003).
9. Maslowski, K.M. et al. Regulation of inflammatory responses by gut microbiota and chemoa ctant receptor GPR43. Nature 461, 1282–1286 (2009).
10. Smith, P.M. et al. The microbial metabolites, short-chain fatty acids, regulate colonic T cell homeostasis. Science 341, 569–573 (2013).
11. Kim, M.H., Kang, S.G., Park, J.H., Yanagisawa, M. & Kim, C.H. Short-chain fatty acids activate GPR41 and GPR43 on intestinal epithelial cells to promote inflammatory responses in mice. Gastroenterology 145, 396–406, e1–10 (2013).
12. Zurina, L.A., Jain, R., Haines, C. & Cua, D.J. Th17 cell development: from the cradle to the grave. Immunol. Rev. 252, 75–88 (2013).
13. McNair, J.P. & Kolls, J.K. Mechanisms controlling Th17 cytokine expression and host defense. J. Leukoc. Biol. 90, 263–270 (2011).
14. Symons, A., Budelsky, A.L. & Towne, J.E. Are Th17 cells in the gut pathogenic or protective?. Mucosal Immunol. 5, 4–6 (2012).
15. Khader, S.A., Gaffen, S.L. & Kolls, J.K. Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa. Mucosal Immunol. 2, 403–411 (2009).
16. Atarashi, K. & Honda, K. Microbiota in autoimmunity and tolerance. Curr. Opin. Immunol. 23, 761–768 (2011).
17. Ivanov, I.I. & Littman, D.R. Segmented filamentous bacteria take the stage. Mucosal Immunol. 3, 209–212 (2010).
18. Sartor, R.B. Key questions to guide a better understanding of host-microbial interactions in intestinal inflammation. Mucosal Immunol. 4, 127–132 (2011).
19. Vinolo, M.A. et al. SCFAs induce mouse neutrophil chemotaxis through the GPR43 receptor. PLoS One 6, e21205 (2011).
20. Kamaranaka, M. et al. Expression of interleukin-10 in intestinal lymphocytes detected by an interleukin-10 reporter knockin tiger mouse. Immunity 25, 941–952 (2006).
21. Merger, M. et al. Defining the roles of perforin, Fas/Fasl., and tumour necrosis factor alpha in T cell induced mucosal damage in the mouse intestine. Gut 51, 155–163 (2002).
22. Tazoe, H., Otomo, Y., Kaji, I., Tanaka, R., Karaki, S.I. & KUWAHARA, A. Roles of short-chain fatty acids receptors, GPR41 and GPR43 on colonic functions. J. Physiol. Pharmacol. 59 (Suppl 2), 251–262 (2008).
23. Keifer, J., Beyer-Sehlmeyer, G. & Pool-Zobel, B.L. Mixtures of SCFA, composed according to physiologically available concentrations in the gut lumen, modulate histone acetylation in human HT29 colon cancer cells. Br. J. Nutr. 96, 803–810 (2006).
24. Hinnebusch, B.F., Meng, S., Wu, J.T., Archer, S.Y. & Hodin, R.A. The effects of short-chain fatty acids on human colon cancer cell phenotype are associated with histone hyperacetylation. J. Nutr. 132, 1012–1017 (2002).

25. Aoyama, M., Kotani, J. & Usami, M. Butyrate and propionate induced activated or non-activated neutrophil apoptosis via HDAC inhibitor activity but without activating GPR-41/GPR-43 pathways. Nutrition 26, 653–661 (2010).

26. Delgoffe, G.M. et al. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 30, 852–864 (2009).

27. Lee, K. Histone acetyltransferases interact with and acetylate p70 ribosomal S6 kinases in vivo. Int. J. Biochem. Cell Biol. 42, 359–366 (2010).

28. Ochanuna, Z., Geiger-Maor, A., Dembinsky-Vaknin, A., Karussis, D., Tykocinski, M.L. & Rachmilewitz, J. Inhibition of effector function but not T cell activation and increase in FoxP3 expression in T cells differentiated in the presence of PP14. PLoS One 5, e12868 (2010).

29. Fenton, T.R., Gwalter, J., Cramer, R. & Gout, I.T. Histone acetyltransferases interact with and acetylate p70 ribosomal S6 kinases in vitro and in vivo. Int. J. Biochem. Cell Biol. 42, 359–366 (2010).

30. Bolster, D.R., Crozier, S.J., Kimball, S.R. & Jefferson, L.S. AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling. J. Biol. Chem. 277, 23977–23980 (2002).

31. Wei, L., Laurence, A. & O’Shea, J.J. New insights into the roles of Stat5a/b and Stat3 in T cell development and differentiation. Sem. Cell Dev. Biol. 19, 394–400 (2008).

32. Saraiva, M., Christensen, J.R., Veldhoen, M., Murphy, T.L., Murphy, K.M. & O’Garra, A. Interleukin-12-induced STAT4 transcription factor and ERK MAP kinase activation by high antigen dose. Immunity 31, 209–219 (2009).

33. Hadijagapiou, C., Schmidt, L., Dudeja, P.K., Layden, T.J. & Ramaswamy, K. Mechanism(s) of butyrate transport in Caco-2 cells: role of monocarboxylate transporter 1. Am. J. Physiol. Gastrointest. Liver Physiol. 279, G775–G780 (2000).

34. Binder, H.J. Role of colonic short-chain fatty acid transport in diarrhea. Annu. Rev. Physiol. 72, 297–313 (2010).

35. Baier, U.H., Akimova, T., Liu, Y., Wang, L. & Hancock, W.W. Histone/protein deacetylases control Foxp3 expression and the heat shock response of T-Regulatory cells. Curr. Opin. Immunol. 23, 670–678 (2011).

36. Haberland, M., Montgomery, R.L. & Olson, E.N. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat. Rev. Genet. 10, 32–42 (2009).

37. Bhavsar, P., Ahmad, T. & Adcock, I.M. The role of histone deacetylases in asthma and allergic diseases. J. Allergy Clin. Immunol. 121, 580–584 (2008).

38. Delgoffe, G.M. et al. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat. Immunol. 12, 295–303 (2011).

39. Haxhinasto, S., Mathis, D. & Benoist, C. The AKT-mTOR axis regulates de novo differentiation of CD4 + Foxp3 + cells. J. Exp. Med. 205, 565–574 (2008).

40. Zeiser, R. et al. Differential impact of mammalian target of rapamycin inhibition on CD4 + CD25 + Foxp3 + regulatory T cells compared with conventional CD4 + T cells. Blood 111, 453–462 (2008).

41. Huss, D.J., Winger, R.C., Peng, H., Yang, Y., Racke, M.K. & Lovett-Racke, A.E. TGF-beta enhances effector Th1 cell activation but promotes self-regulation via IL-10. J. Immunol. 184, 5628–5636 (2010).

42. Jankovic, D., Kugler, D.G. & Sher, A. IL-10 production by CD4 + effector T cells: a mechanism for self-regulation. Mucosal Immunol. 3, 239–246 (2010).

43. Singh, N. et al. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity 40, 128–139 (2014).

44. Atarashi, K. et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature 500, 232–236 (2013).

45. Furusawa, Y. et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504, 446–450 (2013).

46. Arpaia, N. et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 504, 451–455 (2013).

47. Trompette, A. et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat. Med. 20, 159–166 (2014).

48. Symonds, E.L., Riedel, C.U., O’Mahony, D., Lapthorne, S., O’Mahony, L. & Shanahan, F. Involvement of T helper type 17 and regulatory T-cell activity in Citrobacter rodentium invasion and inflammatory damage. Clin. Exp. Immunol. 157, 148–154 (2009).